CollPlant Biotechnologies's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.23.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.02.
During the past 3 years, the average EBIT per Share Growth Rate was 15.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for CollPlant Biotechnologies's EBIT per Share or its related term are showing as below:
CLGN'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -270.4 Med: -16.6 Max: 28.6
Current: 15.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of CollPlant Biotechnologies was 28.60% per year. The lowest was -270.40% per year. And the median was -16.60% per year.
CLGN's 3-Year EBIT Growth Rate is ranked worse than 50.17% of 1174
companies
in the Biotechnology industry
Industry Median: 15.4
vs CLGN: 15.30
CollPlant Biotechnologies (NAS:CLGN) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
CollPlant Biotechnologies EBIT per Share Related Terms
CollPlant Biotechnologies EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CollPlant Biotechnologies (CLGN) has a EBIT per Share of $-1.02 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CollPlant Biotechnologies and its competitors. According to the industry distribution chart, CollPlant Biotechnologies ranks #589 out of 1174 companies in the Biotechnology industry, placing it in the top 50.2%.
Is CollPlant Biotechnologies' EBIT per Share too high?
CollPlant Biotechnologies' current EBIT per Share is $-1.02. Based on the distribution chart, CollPlant Biotechnologies ranks #589 out of 1174 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CollPlant Biotechnologies has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' EBIT per Share compare to CPMV and TCRT?
According to the Biotechnology industry distribution chart, CollPlant Biotechnologies ranks #589 out of 1174 companies for EBIT per Share. This places CollPlant Biotechnologies in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,174 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CollPlant Biotechnologies and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CollPlant Biotechnologies's current EBIT per Share is $-1.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (CLGN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.29, compared to a current price of $0.43 — trading 47.5% above its estimated fair value. The current EBIT per Share is $-1.02. CollPlant Biotechnologies' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For CollPlant Biotechnologies (CLGN), the current EBIT per Share is $-1.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CollPlant Biotechnologies (CLGN) Overvalued in 2026?
Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued.
The current stock price of $0.43 is trading 47.5% above its estimated GF Value™ of $0.29.
GuruFocus considers CollPlant Biotechnologies to be Significantly Overvalued.
Key valuation signals for CLGN:
EBIT per Share: $-1.02
GF Value™: $0.29 vs. price of $0.43 (47.5% above fair value)
No single metric tells the full story. See the CLGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
35GF Score
Get the complete analysis for CLGN
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLGN has been successfully added to your 
